{
    "clinical_study": {
        "@rank": "141107", 
        "arm_group": {
            "arm_group_label": "Metastatic Colorectal Cancer", 
            "description": "Wild-type KRAS confirmed"
        }, 
        "brief_summary": {
            "textblock": "This is a multicenter, observational prospective cohort study in France and Germany.\n      Treatment centres with a focus on treating subjects with mCRC will be prospectively defined\n      for potential inclusion in the study. Eligible subjects will be enrolled and have\n      retrospective data collected from Baseline up to the point of enrolment.  All subsequent\n      chemotherapy cycles and Vectibix\u00ae doses will be recorded prospectively.  Each subject will\n      have data collected until approximately 30 days after the end of Vectibix\u00ae treatment, death,\n      withdrawal of consent, loss to follow-up or up to 12 months from the first dose of\n      Vectibix\u00ae, whichever occurs first."
        }, 
        "brief_title": "Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Wild-type KRAS Metastatic Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          -  Subject is \u2265 18 years of age at date of enrolment\n\n          -  Histologically or cytologically confirmed carcinoma of colon or rectum\n\n          -  Subject with metastatic carcinoma of colon or rectum\n\n          -  Confirmed wild-type KRAS status of tumour\n\n          -  Subjects whose care will be managed primarily by the enrolling physician and/ or all\n             records will be available\n\n          -  Tumour assessment (ie, CT/MRI) within 12 weeks (84 days) prior to first Vectibix\u00ae\n             infusion.\n\n          -  Subjects treated with at least one infusion of Vectibix\u00ae in combination with\n             chemotherapy a maximum of 42 days before entering study: first-line in combination\n             with FOLFOX or second-line in combination with FOLFIRI in subjects who have received\n             first-line fluoropyrimidine-based chemotherapy (excluding irinotecan) for treatment\n             of wild-type KRAS mCRC per approved prescribing information\n\n          -  Subject or subject's legally acceptable representative has provided informed consent\n             (for countries where required per local regulations)\n\n        Exclusion Criteria\n\n          -  Ongoing or planned concurrent participation in any clinical study involving\n             Investigational Product that has not been approved by the European Medicines Agency\n             for any indication\n\n          -  Ongoing or planned concurrent participation in any clinical study where the dosing of\n             Vectibix\u00ae is determined by the protocol (participation in clinical trials on an\n             approved drug and observational trials are permitted but these cannot mandate how\n             mCRC should be treated)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "All treatment centres (inpatient and outpatient) with a focus on treating subjects with\n        mCRC. Centres will be selected to represent academic, oncology and specialist settings and\n        to provide geographical diversity in France and Germany."
            }
        }, 
        "enrollment": {
            "#text": "740", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732783", 
            "org_study_id": "20120100"
        }, 
        "intervention": {
            "arm_group_label": "Metastatic Colorectal Cancer", 
            "description": "Observational of the Use of Vectibix\u00ae in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type KRAS Metastatic Colorectal Cancer", 
            "intervention_name": "Observational", 
            "intervention_type": "Other"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Wild-type KRAS", 
            "Metastatic Colorectal Cancer", 
            "Vectibix"
        ], 
        "lastchanged_date": "January 22, 2014", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Observational Cohort Study to Describe the Use of Vectibix\u00ae in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type KRAS Metastatic Colorectal Cancer", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": [
                "Germany: Paul-Ehrlich-Institut (PEI)", 
                "Germany: Kassen\u00e4rztliche Bundesvereinigung (KBV)", 
                "Germany: Gesetzliche Krankenversicherung (GKV)", 
                "Germany: Ethik-Kommission der Bayerischen Landes\u00e4rztekammer", 
                "Germany: Verband der Privaten Krankenversicherung e.V. (PKV)", 
                "France: Comite consultatif sur le traitement de l'information en mati\u00e8re de recherche dans le domaine de la sant\u00e9 (CCTIRS)", 
                "France: Commission nationale de l'informatique et des libert\u00e9s (CNIL)", 
                "France: Conseil National de l'Ordre des M\u00e9decins (CNOM)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Type of chemotherapy combined with Vectibix\u00ae Starting dose and administration schedule of Vectibix\u00ae and chemotherapy Cumulative dose, maximum dose, duration of exposure and total number of infusions received of Vectibix\u00ae therapy and chemotherapy Dose reductions and/or delays and reason(s) for of Vectibix\u00ae and/or chemotherapy Discontinuation and reason(s) for discontinuation of Vectibix\u00ae and chemotherapy", 
            "measure": "Treatment patterns of Vectibix\u00ae and concomitant chemotherapy for mCRC", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732783"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Including type of visit and reason for hospitalisation", 
                "measure": "Healthcare resource utilization", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Demographics, disease characteristics, co-morbidities, individual treatment goals and prior treatment history", 
                "measure": "Demography of disease population", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "including best response, conversion to resectability, and by individual treatment goals", 
                "measure": "Response to Vectibix\u00ae", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Summaries of planned anti-cancer treatment initiated post Vectibix\u00ae discontinuation", 
                "measure": "Planned anti-cancer treatment initiated post Vectibix", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}